U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H24N4O.ClH
Molecular Weight 348.87
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GRANISETRON HYDROCHLORIDE

SMILES

Cl.CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C4=CC=CC=C14

InChI

InChIKey=QYZRTBKYBJRGJB-WQTKJZBYSA-N
InChI=1S/C18H24N4O.ClH/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17;/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23);1H/t12-,13+,14-;

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022445s000lbl.pdf

Granisetron is a selective inhibitor of type 3 serotonergic (5-HT3) receptors. The drug is structurally and pharmacologically related to ondansetron, another selective inhibitor of 5-HT3 receptors. The serontonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery, and centrally in the chemoreceptor trigger zone of the area postrema. The temporal relationship between the emetogenic action of emetogenic drugs and the release of serotonin, as well as the efficacy of antiemetic agents suggest that chemotherapeutic agents release serotonin from the enterochromaffin cells of the small intestine by causing degenerative changes in the GI tract. The serotonin then stimulates the vagal and splanchnic nerve receptors that project to the medullary vomiting center, as well as the 5-HT3 receptors in the area postrema, thus initiating the vomiting reflex, causing nausea and vomiting. Granisetron is a potent, selective antagonist of 5-HT3 receptors. The antiemetic activity of the drug is brought about through the inhibition of 5-HT3 receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT3 receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone. Granisetron is used for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation).

CNS Activity

CNS Penetrant
2554
Curator's Comment: The increasing brain/blood concentration ratio of granisetron suggests that granisetron penetrates the blood-brain barrier in rats.

Originator

Approval Year

1993
136
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
 1.45 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
Approved
8429
SUSTOL

Approved Use

SUSTOL is a serotonin-3 (5-HT3) receptor antagonist indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.

Launch Date

1992
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4.948 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/22452942
10 μg/kg bw single, intravenous
dose: 10 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GRANISETRON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
36.87 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/22452942
10 μg/kg bw single, intravenous
dose: 10 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GRANISETRON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/22452942
10 μg/kg bw single, intravenous
dose: 10 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GRANISETRON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 mg 2 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7758060/
unhealthy, 50.6 years (range: 23-76 years)
n = 233
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 50.6 years (range: 23-76 years)
Sex: M+F
Population Size: 233
Sources:
https://pubmed.ncbi.nlm.nih.gov/7758060/
Other AEs: Constipation, Headache...
Other AEs:
Constipation (27.5%)
Headache (17.6%)
Leukopenia (15%)
Asthenia (6.9%)
Abdominal pain (9%)
Decreased appetite (5.6%)
Anemia (1.3%)
Diarrhea (4.3%)
Abnormal liver function tests (2.6%)
Alopecia (3%)
Pain (0.4%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7758060/
160 ug/kg single, intravenous
Highest studied dose
Dose: 160 ug/kg
Route: intravenous
Route: single
Dose: 160 ug/kg
Co-administed with::
cisplatin(>50 mg/m^2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/8032704/
unhealthy, 54
n = 165
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 54
Sex: M+F
Population Size: 165
Sources:
https://pubmed.ncbi.nlm.nih.gov/8032704/
Other AEs: Headache, Constipation...
Other AEs:
Headache (13.9%)
Constipation (4.2%)
Somnolence (2.4%)
Dizziness (1.2%)
Dyspepsia (1.8%)
Back pain (3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/8032704/
15 mg single, subcutaneous
Highest studied dose
Dose: 15 mg
Route: subcutaneous
Route: single
Dose: 15 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
unhealthy, 64.3
n = 13
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 64.3
Sex: M+F
Population Size: 13
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
Other AEs: Constipation, Diarrhea...
Other AEs:
Constipation (23.1%)
Diarrhea (15.4%)
Headache (30.8%)
Fatigue (15.4%)
Anorexia (15.4%)
Weight loss (7.7%)
Dizziness (7.7%)
Neutropenia (15.4%)
Mucosal inflammation (15.4%)
Dyspnea (7.7%)
Insomnia (7.7%)
Thrombocytopenia (7.7%)
Injection site bruising (7.7%)
Pain injection site (2.2%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
1 mg single, intravenous
Recommended
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 267
Health Status: unhealthy
Condition: nausea and vomiting, postoperative
Population Size: 267
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Other AEs: Pain, Constipation...
Other AEs:
Pain (10.1%)
Constipation (9.4%)
Anemia (9.4%)
Headache (8.6%)
Fever (7.9%)
Abdominal pain (6%)
Hepatic enzymes increased (5.6%)
Insomnia (4.9%)
Bradycardia (4.5%)
Dizziness (4.1%)
Leukocytosis (3.7%)
Anxiety (3.4%)
Hypotension (3.4%)
Diarrhea (3.4%)
Flatulence (3%)
Infection (3%)
Dyspepsia (3%)
Hypertension (2.6%)
Urinary tract infection (2.6%)
Oliguria (2.2%)
Coughing (2.2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
40 ug/kg single, intravenous
Recommended
Dose: 40 ug/kg
Route: intravenous
Route: single
Dose: 40 ug/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 1268
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Population Size: 1268
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Other AEs: Headache, Asthenia...
Other AEs:
Headache (14%)
Asthenia (5%)
Somnolence (4%)
Diarrhea (4%)
Constipation (3%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Pain 0.4%
2 mg 2 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7758060/
unhealthy, 50.6 years (range: 23-76 years)
n = 233
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 50.6 years (range: 23-76 years)
Sex: M+F
Population Size: 233
Sources:
https://pubmed.ncbi.nlm.nih.gov/7758060/
Anemia 1.3%
2 mg 2 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7758060/
unhealthy, 50.6 years (range: 23-76 years)
n = 233
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 50.6 years (range: 23-76 years)
Sex: M+F
Population Size: 233
Sources:
https://pubmed.ncbi.nlm.nih.gov/7758060/
Leukopenia 15%
2 mg 2 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7758060/
unhealthy, 50.6 years (range: 23-76 years)
n = 233
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 50.6 years (range: 23-76 years)
Sex: M+F
Population Size: 233
Sources:
https://pubmed.ncbi.nlm.nih.gov/7758060/
Headache 17.6%
2 mg 2 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7758060/
unhealthy, 50.6 years (range: 23-76 years)
n = 233
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 50.6 years (range: 23-76 years)
Sex: M+F
Population Size: 233
Sources:
https://pubmed.ncbi.nlm.nih.gov/7758060/
Abnormal liver function tests 2.6%
2 mg 2 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7758060/
unhealthy, 50.6 years (range: 23-76 years)
n = 233
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 50.6 years (range: 23-76 years)
Sex: M+F
Population Size: 233
Sources:
https://pubmed.ncbi.nlm.nih.gov/7758060/
Constipation 27.5%
2 mg 2 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7758060/
unhealthy, 50.6 years (range: 23-76 years)
n = 233
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 50.6 years (range: 23-76 years)
Sex: M+F
Population Size: 233
Sources:
https://pubmed.ncbi.nlm.nih.gov/7758060/
Alopecia 3%
2 mg 2 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7758060/
unhealthy, 50.6 years (range: 23-76 years)
n = 233
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 50.6 years (range: 23-76 years)
Sex: M+F
Population Size: 233
Sources:
https://pubmed.ncbi.nlm.nih.gov/7758060/
Diarrhea 4.3%
2 mg 2 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7758060/
unhealthy, 50.6 years (range: 23-76 years)
n = 233
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 50.6 years (range: 23-76 years)
Sex: M+F
Population Size: 233
Sources:
https://pubmed.ncbi.nlm.nih.gov/7758060/
Decreased appetite 5.6%
2 mg 2 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7758060/
unhealthy, 50.6 years (range: 23-76 years)
n = 233
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 50.6 years (range: 23-76 years)
Sex: M+F
Population Size: 233
Sources:
https://pubmed.ncbi.nlm.nih.gov/7758060/
Asthenia 6.9%
2 mg 2 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7758060/
unhealthy, 50.6 years (range: 23-76 years)
n = 233
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 50.6 years (range: 23-76 years)
Sex: M+F
Population Size: 233
Sources:
https://pubmed.ncbi.nlm.nih.gov/7758060/
Abdominal pain 9%
2 mg 2 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7758060/
unhealthy, 50.6 years (range: 23-76 years)
n = 233
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 50.6 years (range: 23-76 years)
Sex: M+F
Population Size: 233
Sources:
https://pubmed.ncbi.nlm.nih.gov/7758060/
Dizziness 1.2%
160 ug/kg single, intravenous
Highest studied dose
Dose: 160 ug/kg
Route: intravenous
Route: single
Dose: 160 ug/kg
Co-administed with::
cisplatin(>50 mg/m^2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/8032704/
unhealthy, 54
n = 165
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 54
Sex: M+F
Population Size: 165
Sources:
https://pubmed.ncbi.nlm.nih.gov/8032704/
Dyspepsia 1.8%
160 ug/kg single, intravenous
Highest studied dose
Dose: 160 ug/kg
Route: intravenous
Route: single
Dose: 160 ug/kg
Co-administed with::
cisplatin(>50 mg/m^2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/8032704/
unhealthy, 54
n = 165
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 54
Sex: M+F
Population Size: 165
Sources:
https://pubmed.ncbi.nlm.nih.gov/8032704/
Headache 13.9%
160 ug/kg single, intravenous
Highest studied dose
Dose: 160 ug/kg
Route: intravenous
Route: single
Dose: 160 ug/kg
Co-administed with::
cisplatin(>50 mg/m^2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/8032704/
unhealthy, 54
n = 165
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 54
Sex: M+F
Population Size: 165
Sources:
https://pubmed.ncbi.nlm.nih.gov/8032704/
Somnolence 2.4%
160 ug/kg single, intravenous
Highest studied dose
Dose: 160 ug/kg
Route: intravenous
Route: single
Dose: 160 ug/kg
Co-administed with::
cisplatin(>50 mg/m^2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/8032704/
unhealthy, 54
n = 165
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 54
Sex: M+F
Population Size: 165
Sources:
https://pubmed.ncbi.nlm.nih.gov/8032704/
Back pain 3%
160 ug/kg single, intravenous
Highest studied dose
Dose: 160 ug/kg
Route: intravenous
Route: single
Dose: 160 ug/kg
Co-administed with::
cisplatin(>50 mg/m^2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/8032704/
unhealthy, 54
n = 165
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 54
Sex: M+F
Population Size: 165
Sources:
https://pubmed.ncbi.nlm.nih.gov/8032704/
Constipation 4.2%
160 ug/kg single, intravenous
Highest studied dose
Dose: 160 ug/kg
Route: intravenous
Route: single
Dose: 160 ug/kg
Co-administed with::
cisplatin(>50 mg/m^2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/8032704/
unhealthy, 54
n = 165
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 54
Sex: M+F
Population Size: 165
Sources:
https://pubmed.ncbi.nlm.nih.gov/8032704/
Anorexia 15.4%
15 mg single, subcutaneous
Highest studied dose
Dose: 15 mg
Route: subcutaneous
Route: single
Dose: 15 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
unhealthy, 64.3
n = 13
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 64.3
Sex: M+F
Population Size: 13
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
Diarrhea 15.4%
15 mg single, subcutaneous
Highest studied dose
Dose: 15 mg
Route: subcutaneous
Route: single
Dose: 15 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
unhealthy, 64.3
n = 13
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 64.3
Sex: M+F
Population Size: 13
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
Fatigue 15.4%
15 mg single, subcutaneous
Highest studied dose
Dose: 15 mg
Route: subcutaneous
Route: single
Dose: 15 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
unhealthy, 64.3
n = 13
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 64.3
Sex: M+F
Population Size: 13
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
Mucosal inflammation 15.4%
15 mg single, subcutaneous
Highest studied dose
Dose: 15 mg
Route: subcutaneous
Route: single
Dose: 15 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
unhealthy, 64.3
n = 13
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 64.3
Sex: M+F
Population Size: 13
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
Neutropenia 15.4%
15 mg single, subcutaneous
Highest studied dose
Dose: 15 mg
Route: subcutaneous
Route: single
Dose: 15 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
unhealthy, 64.3
n = 13
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 64.3
Sex: M+F
Population Size: 13
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
Pain injection site 2.2%
15 mg single, subcutaneous
Highest studied dose
Dose: 15 mg
Route: subcutaneous
Route: single
Dose: 15 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
unhealthy, 64.3
n = 13
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 64.3
Sex: M+F
Population Size: 13
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
Constipation 23.1%
15 mg single, subcutaneous
Highest studied dose
Dose: 15 mg
Route: subcutaneous
Route: single
Dose: 15 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
unhealthy, 64.3
n = 13
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 64.3
Sex: M+F
Population Size: 13
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
Headache 30.8%
15 mg single, subcutaneous
Highest studied dose
Dose: 15 mg
Route: subcutaneous
Route: single
Dose: 15 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
unhealthy, 64.3
n = 13
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 64.3
Sex: M+F
Population Size: 13
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
Dizziness 7.7%
15 mg single, subcutaneous
Highest studied dose
Dose: 15 mg
Route: subcutaneous
Route: single
Dose: 15 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
unhealthy, 64.3
n = 13
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 64.3
Sex: M+F
Population Size: 13
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
Dyspnea 7.7%
15 mg single, subcutaneous
Highest studied dose
Dose: 15 mg
Route: subcutaneous
Route: single
Dose: 15 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
unhealthy, 64.3
n = 13
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 64.3
Sex: M+F
Population Size: 13
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
Injection site bruising 7.7%
15 mg single, subcutaneous
Highest studied dose
Dose: 15 mg
Route: subcutaneous
Route: single
Dose: 15 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
unhealthy, 64.3
n = 13
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 64.3
Sex: M+F
Population Size: 13
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
Insomnia 7.7%
15 mg single, subcutaneous
Highest studied dose
Dose: 15 mg
Route: subcutaneous
Route: single
Dose: 15 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
unhealthy, 64.3
n = 13
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 64.3
Sex: M+F
Population Size: 13
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
Thrombocytopenia 7.7%
15 mg single, subcutaneous
Highest studied dose
Dose: 15 mg
Route: subcutaneous
Route: single
Dose: 15 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
unhealthy, 64.3
n = 13
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 64.3
Sex: M+F
Population Size: 13
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
Weight loss 7.7%
15 mg single, subcutaneous
Highest studied dose
Dose: 15 mg
Route: subcutaneous
Route: single
Dose: 15 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
unhealthy, 64.3
n = 13
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Age Group: 64.3
Sex: M+F
Population Size: 13
Sources:
https://pubmed.ncbi.nlm.nih.gov/25834466/
Pain 10.1%
1 mg single, intravenous
Recommended
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 267
Health Status: unhealthy
Condition: nausea and vomiting, postoperative
Population Size: 267
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Coughing 2.2%
1 mg single, intravenous
Recommended
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 267
Health Status: unhealthy
Condition: nausea and vomiting, postoperative
Population Size: 267
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Oliguria 2.2%
1 mg single, intravenous
Recommended
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 267
Health Status: unhealthy
Condition: nausea and vomiting, postoperative
Population Size: 267
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Hypertension 2.6%
1 mg single, intravenous
Recommended
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 267
Health Status: unhealthy
Condition: nausea and vomiting, postoperative
Population Size: 267
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Urinary tract infection 2.6%
1 mg single, intravenous
Recommended
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 267
Health Status: unhealthy
Condition: nausea and vomiting, postoperative
Population Size: 267
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Dyspepsia 3%
1 mg single, intravenous
Recommended
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 267
Health Status: unhealthy
Condition: nausea and vomiting, postoperative
Population Size: 267
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Flatulence 3%
1 mg single, intravenous
Recommended
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 267
Health Status: unhealthy
Condition: nausea and vomiting, postoperative
Population Size: 267
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Infection 3%
1 mg single, intravenous
Recommended
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 267
Health Status: unhealthy
Condition: nausea and vomiting, postoperative
Population Size: 267
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Anxiety 3.4%
1 mg single, intravenous
Recommended
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 267
Health Status: unhealthy
Condition: nausea and vomiting, postoperative
Population Size: 267
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Diarrhea 3.4%
1 mg single, intravenous
Recommended
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 267
Health Status: unhealthy
Condition: nausea and vomiting, postoperative
Population Size: 267
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Hypotension 3.4%
1 mg single, intravenous
Recommended
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 267
Health Status: unhealthy
Condition: nausea and vomiting, postoperative
Population Size: 267
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Leukocytosis 3.7%
1 mg single, intravenous
Recommended
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 267
Health Status: unhealthy
Condition: nausea and vomiting, postoperative
Population Size: 267
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Dizziness 4.1%
1 mg single, intravenous
Recommended
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 267
Health Status: unhealthy
Condition: nausea and vomiting, postoperative
Population Size: 267
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Bradycardia 4.5%
1 mg single, intravenous
Recommended
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 267
Health Status: unhealthy
Condition: nausea and vomiting, postoperative
Population Size: 267
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Insomnia 4.9%
1 mg single, intravenous
Recommended
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 267
Health Status: unhealthy
Condition: nausea and vomiting, postoperative
Population Size: 267
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Hepatic enzymes increased 5.6%
1 mg single, intravenous
Recommended
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 267
Health Status: unhealthy
Condition: nausea and vomiting, postoperative
Population Size: 267
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Abdominal pain 6%
1 mg single, intravenous
Recommended
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 267
Health Status: unhealthy
Condition: nausea and vomiting, postoperative
Population Size: 267
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Fever 7.9%
1 mg single, intravenous
Recommended
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 267
Health Status: unhealthy
Condition: nausea and vomiting, postoperative
Population Size: 267
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Headache 8.6%
1 mg single, intravenous
Recommended
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 267
Health Status: unhealthy
Condition: nausea and vomiting, postoperative
Population Size: 267
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Anemia 9.4%
1 mg single, intravenous
Recommended
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 267
Health Status: unhealthy
Condition: nausea and vomiting, postoperative
Population Size: 267
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Constipation 9.4%
1 mg single, intravenous
Recommended
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 267
Health Status: unhealthy
Condition: nausea and vomiting, postoperative
Population Size: 267
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Headache 14%
40 ug/kg single, intravenous
Recommended
Dose: 40 ug/kg
Route: intravenous
Route: single
Dose: 40 ug/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 1268
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Population Size: 1268
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Constipation 3%
40 ug/kg single, intravenous
Recommended
Dose: 40 ug/kg
Route: intravenous
Route: single
Dose: 40 ug/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 1268
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Population Size: 1268
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Diarrhea 4%
40 ug/kg single, intravenous
Recommended
Dose: 40 ug/kg
Route: intravenous
Route: single
Dose: 40 ug/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 1268
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Population Size: 1268
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Somnolence 4%
40 ug/kg single, intravenous
Recommended
Dose: 40 ug/kg
Route: intravenous
Route: single
Dose: 40 ug/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 1268
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Population Size: 1268
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Asthenia 5%
40 ug/kg single, intravenous
Recommended
Dose: 40 ug/kg
Route: intravenous
Route: single
Dose: 40 ug/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
unhealthy
n = 1268
Health Status: unhealthy
Condition: nausea and vomiting, chemotherapy-Induced
Population Size: 1268
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1737
substrate
1037
substrate
1217
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A1
349

CYP1A2
1054

CYP1B1
92

CYP2A6
543

CYP2B6
664

CYP2C8
693

CYP2C18
138

CYP2C19
991

CYP2E1
667

CYP2J2
56

CYP3A5
395

CYP3A7
110
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1054
 likely
CYP1B1
92
 likely
CYP2B6
664
 likely
CYP2C19
991
 likely
CYP2C8
693
 likely
CYP2D6
1217
 likely
CYP2J2
56
 likely
CYP3A5
395
 likely
CYP3A7
110
 likely
CYP1A1
349
 major
unknown (co-administration study)
Comment: Administration of intravenous granisetron hydrochloride with phenobarbital, an enzyme inducer, resulted in a 25% increase in total plasma clearance of granisetron. The clinical significance of this interaction is not known.
Page: 113.0
CYP3A4
1737
 minor
unknown (co-administration study)
Comment: the potential for an in vivo pharmacokinetic interaction with ketoconazole is not known; Administration of intravenous granisetron hydrochloride with phenobarbital, an enzyme inducer, resulted in a 25% increase in total plasma clearance of granisetron. The clinical significance of this interaction is not known.
Page: 113.0
CYP2A6
543
 no
CYP2C18
138
 no
CYP2C9
1037
 no
CYP2E1
667
 no
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:5537
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5537
ChemicalBook
CB2728852
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2728852
ZINC
ZINC000100018854
http://zinc15.docking.org/substances/ZINC000100018854
eMolecules
32452667
https://www.emolecules.com/cgi-bin/more?vid=32452667
PubMed

PubMed

TitleDatePubMed
Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation.
2001
Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis.
2001 Dec
Effects of nutrients and serotonin 5-HT3 antagonism on symptoms evoked by distal gastric distension in humans.
2001 Feb
Intestinal serotonin acts as a paracrine substance to mediate vagal signal transmission evoked by luminal factors in the rat.
2001 Feb 1
Prophylaxis with oral granisetron for the prevention of nausea and vomiting after laparoscopic cholecystectomy: a prospective randomized study.
2001 Jan
Manifest Anxiety Scale for evaluation of effects of granisetron in chemotherapy with CDDP and 5FU for head and neck cancer.
2001 Jul
A placebo-controlled, crossover trial of granisetron in SRI-induced sexual dysfunction.
2001 Jun
Preoperative oral granisetron for the prevention of postoperative nausea and vomiting after breast surgery.
2001 Mar
Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.
2001 Mar 15
Barostat examination of proximal site of the anastomosis in patients with rectal cancer after low anterior resection.
2001 Nov
Characterization of the receptors involved in the 5-HT-induced excitation of canine antral longitudinal muscle.
2001 Nov
Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks.
2001 Oct
Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers.
2002
Effects of ondansetron, granisetron, ramosetron, and azasetron on human neutrophil functions.
2002
Sensitization of enteric reflexes in the rat colon in vitro.
2002 Apr 18
Emerging treatments for irritable bowel syndrome.
2002 Jan
ATP and 5-HT are the principal neurotransmitters in the descending excitatory reflex pathway of the guinea-pig ileum.
2002 Jun
Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy.
2002 Jun
Functional group interactions of a 5-HT3R antagonist.
2002 Jun 13
Preoperative oral granisetron for the prevention of vomiting following paediatric surgery.
2002 Mar
Gateways to clinical trials.
2002 May
Comparison of granisetron and ramosetron for the prevention of nausea and vomiting after thyroidectomy.
2002 May
A dose-finding study of carboplatin-epirubicin-docetaxel in advanced epithelial ovarian cancer.
2002 May 6
Oral granisetron revisited.
2002 Nov
Motilin regulates interdigestive gastric blood flow in dogs.
2002 Nov
Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer.
2002 Nov 4
Compatibility and stability of 5-HT3 receptor antagonists: a pharmacology review.
2002 Nov-Dec
Prophylactic antiemetic efficacy of granisetron or ramosetron in patients undergoing thyroidectomy.
2002 Oct
[Nausea disintegrating buccal tablet in the prevention of gastrointestinal reaction induced by anticancer drugs].
2002 Sep
In vivo assessment of acceleration of motor activity associated with acetylcholine release via 5-hydroxytryptamine4 receptor in dog intestine.
2002 Sep
Treatment of vomiting after paediatric strabismus surgery with granisetron, droperidol, and metoclopramide.
2002 Sep-Oct
5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications.
2002 Sep-Oct
Severe pruritus in a haemodialysed patient: dramatic improvement with granisetron.
2003 Feb
Effects on muscle pain by intramuscular injection of granisetron in patients with fibromyalgia.
2003 Feb
A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis.
2003 Feb
Granisetron: relating pharmacology to clinical efficacy.
2003 Feb
Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme.
2003 Feb 24
Granisetron plus dexamethasone versus granisetron alone in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study.
2003 Jan
Comparison of granisetron and granisetron plus dexamethasone for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy.
2003 Jan
Pharmacological characterization of the 5-HT1A, 5-HT2 and 5-HT3 receptors in the bovine ciliary muscle.
2003 Mar 7
Patents

Patents

JP2004513061A
11
JP2006516976A
30

Sample Use Guides

In Vivo Use Guide
IV: 10 mcg/kg over 5 minutes, beginning 30 minutes before initiation of chemotherapy. Orally: 2 mg, given up to 1 hour before chemotherapy, or 1 mg twice a day (the first dose is given up to 1 hour before chemotherapy, and the second dose is given 12 hours later). Granisetron transdermal system: Apply a single patch to the upper outer arm a minimum of 24 hours before chemotherapy. The patch may be applied up to a maximum of 48 hours before chemotherapy as appropriate. Remove the patch a minimum of 24 hours after completion of chemotherapy. The patch can be worn for up to 7 days depending on the duration of the chemotherapy regimen. Granisetron transdermal system is a 52 cm2 patch containing 34.3 mg of granisetron. The patch releases 3.1 mg of granisetron per 24 hours for up to 7 days.
Route of Administration: Other
In Vitro Use Guide
Granisetron (1 uM) shifted the response curves to mucosally applied 5-HT to the right in a parallel and surmountable manner in the guinea pig isolated ileum.
Name Type Language
GRANISETRON HYDROCHLORIDE
USP  
Official Name English
GRANISETRON HYDROCHLORIDE [MI]
Common Name English
NSC-759839
Code English
GRANISETRON HYDROCHLORIDE [JAN]
Common Name English
GRANISETRON HYDROCHLORIDE [USAN]
Common Name English
GRANISETRON HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
GRANISETRON (AS HYDROCHLORIDE)
Common Name English
GRANISETRON HYDROCHLORIDE [MART.]
Common Name English
GRANISETRON HYDROCHLORIDE [USP-RS]
Common Name English
GRANISETRON HYDROCHLORIDE [VANDF]
Common Name English
BRL 43694A
Code English
GRANISETRON HYDROCHLORIDE [USP IMPURITY]
Common Name English
BEMA GRANISETRON
Brand Name English
1H-INDAZOLE-3-CARBOXAMIDE, 1-METHYL-N-(9-METHYL-9-AZABICYCLO(3.3.1)NON-3-YL)-, MONOHYDROCHLORIDE, ENDO-
Common Name English
Granisetron hydrochloride [WHO-DD]
Common Name English
1-METHYL-N-(9-METHYL-ENDO-9-AZABICYCLO(3.3.1)NON-3-YL)-1H-INDAZOLE-3-CARBOXAMIDE MONOHYDROCHLORIDE
Common Name English
GRANISETRON HYDROCHLORIDE [ORANGE BOOK]
Common Name English
GRANISETRON HCL
Common Name English
GRANISETRON HYDROCHLORIDE [EP IMPURITY]
Common Name English
GRANISETRON HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
KYTRIL
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C267
Created by admin on Fri Dec 15 15:51:24 GMT 2023 , Edited by admin on Fri Dec 15 15:51:24 GMT 2023
NCI_THESAURUS C94726
Created by admin on Fri Dec 15 15:51:24 GMT 2023 , Edited by admin on Fri Dec 15 15:51:24 GMT 2023
Code System Code Type Description
FDA UNII
318F6L70J8
Created by admin on Fri Dec 15 15:51:24 GMT 2023 , Edited by admin on Fri Dec 15 15:51:24 GMT 2023
PRIMARY
USAN
DD-90
Created by admin on Fri Dec 15 15:51:24 GMT 2023 , Edited by admin on Fri Dec 15 15:51:24 GMT 2023
PRIMARY
ChEMBL
CHEMBL289469
Created by admin on Fri Dec 15 15:51:24 GMT 2023 , Edited by admin on Fri Dec 15 15:51:24 GMT 2023
PRIMARY
NSC
759839
Created by admin on Fri Dec 15 15:51:24 GMT 2023 , Edited by admin on Fri Dec 15 15:51:24 GMT 2023
PRIMARY
PUBCHEM
6918003
Created by admin on Fri Dec 15 15:51:24 GMT 2023 , Edited by admin on Fri Dec 15 15:51:24 GMT 2023
PRIMARY
MERCK INDEX
m5842
Created by admin on Fri Dec 15 15:51:24 GMT 2023 , Edited by admin on Fri Dec 15 15:51:24 GMT 2023
PRIMARY Merck Index
DAILYMED
318F6L70J8
Created by admin on Fri Dec 15 15:51:24 GMT 2023 , Edited by admin on Fri Dec 15 15:51:24 GMT 2023
PRIMARY
DRUG BANK
DBSALT000485
Created by admin on Fri Dec 15 15:51:24 GMT 2023 , Edited by admin on Fri Dec 15 15:51:24 GMT 2023
PRIMARY
RS_ITEM_NUM
1298106
Created by admin on Fri Dec 15 15:51:24 GMT 2023 , Edited by admin on Fri Dec 15 15:51:24 GMT 2023
PRIMARY
EVMPD
SUB02405MIG
Created by admin on Fri Dec 15 15:51:24 GMT 2023 , Edited by admin on Fri Dec 15 15:51:24 GMT 2023
PRIMARY
RXCUI
142149
Created by admin on Fri Dec 15 15:51:24 GMT 2023 , Edited by admin on Fri Dec 15 15:51:24 GMT 2023
PRIMARY RxNorm
NCI_THESAURUS
C1353
Created by admin on Fri Dec 15 15:51:24 GMT 2023 , Edited by admin on Fri Dec 15 15:51:24 GMT 2023
PRIMARY
CAS
107007-99-8
Created by admin on Fri Dec 15 15:51:24 GMT 2023 , Edited by admin on Fri Dec 15 15:51:24 GMT 2023
PRIMARY
EPA CompTox
DTXSID7049057
Created by admin on Fri Dec 15 15:51:24 GMT 2023 , Edited by admin on Fri Dec 15 15:51:24 GMT 2023
PRIMARY
SMS_ID
100000090454
Created by admin on Fri Dec 15 15:51:24 GMT 2023 , Edited by admin on Fri Dec 15 15:51:24 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of GRANISETRON
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966